Olaratumab: a platelet-derived growth factor receptor-α-blocking antibody for the treatment of soft tissue sarcoma

The outcome of patients with unresectable or metastatic soft tissue sarcoma (STS) remains poor with few treatment options. A number of randomized trials in the first-line setting have shown no difference in overall survival between combination anthracycline schedules and single-agent doxorubicin. A...

Descripción completa

Detalles Bibliográficos
Autores principales: Pender, Alexandra, Jones, Robin L
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2017
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5720043/
https://www.ncbi.nlm.nih.gov/pubmed/29270033
http://dx.doi.org/10.2147/CPAA.S130178

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5720043/
https://www.ncbi.nlm.nih.gov/pubmed/29270033
http://dx.doi.org/10.2147/CPAA.S130178

Ejemplares similares